Phaarmasia Ltd. (PHRMASI) — Tipsheet

Phaarmasia's ₹17.57 cr profit is a one-off land sale

Tipsheet Editorial — Fri, 29 May 2026 19:37:36 GMT

The nano-cap swung to profit on a ₹18.99 cr asset disposal, while operational revenue nearly doubled to ₹47.21 cr.

What’s new

Phaarmasia swung to a net profit of ₹17.57 cr from a loss of ₹1.59 cr a year earlier.
The turnaround was driven by a one-off ₹18.99 cr gain from selling land and buildings.
Operational revenue nearly doubled to ₹47.21 cr; the company ended the year with zero debt and ₹10.99 cr cash.

Why it matters

Strip out the asset sale, and Phaarmasia is a tiny pharma company with ₹47 cr in revenue and a market cap of ₹53 cr. The land sale generated a gain equal to 36% of its entire market capitalisation, dwarfing its operational performance. That's where the profit came from.

What we’re watching

Whether operational revenue growth can sustain its near-doubling pace without asset sales.
How the company deploys its new ₹10.99 cr cash pile.
The next quarterly results to gauge the core business trajectory.

The full read

Phaarmasia's headline numbers look strong. A ₹17.57 cr profit versus a ₹1.59 cr loss. Revenue nearly doubled to ₹47.21 cr. Cash jumped from ₹0.36 cr to ₹10.99 cr. The catch is the source of the profit. The company sold land and buildings for a one-off gain of ₹18.99 cr. That single transaction was 107% of the reported net profit. For a ₹53 cr nano-cap, the gain alone was equivalent to 36% of its market capitalisation. The core pharma business, while growing revenue, did not generate the profit on its own. The balance sheet is now debt-free with a meaningful cash pile, but that's a function of the asset sale, not operational cash flow. The filing says nothing about repeatable earnings power.

Primary source: BSE · NSE

Phaarmasia's ₹18.99 cr land sale flips a ₹1.59 cr loss into a ₹17.57 cr profit

Tipsheet Editorial — Fri, 29 May 2026 19:32:01 GMT

The pharmaceutical company's full-year profit is almost entirely a one-off from an asset sale. Operational revenue grew 94% to ₹47.21 crore, but the land gain is the story.

What’s new

Phaarmasia swung to a net profit of ₹17.57 crore from a ₹1.59 crore loss in the prior year.
An exceptional gain of ₹18.99 crore from a land and building sale drove the turnaround.
Revenue nearly doubled to ₹47.21 crore, and cash reserves surged from ₹0.36 crore to ₹10.99 crore.

Why it matters

The headline profit is almost entirely a one-off event. Strip out the ₹18.99 crore land gain, and the company's core operations were barely breakeven. The sale provided a massive liquidity boost to a ₹53 crore market-cap firm, but it also masks the underlying profitability story.

What we’re watching

Whether the land sale proceeds are deployed for core operations or sit as cash.
If revenue growth can sustain without further asset sales to boost the bottom line.
The company's quarterly operational performance now that the one-off is behind it.

The full read

Phaarmasia's profit is a house built on a one-off. The ₹17.57 crore net profit for FY26 flips a ₹1.59 crore loss, but the ₹18.99 crore gain from selling land and buildings does the heavy lifting. That gain alone is 35% of the company's ₹53 crore market cap. The operational story is real: revenue grew 94% to ₹47.21 crore. But the bottom line was made by the asset sale, not the pharmaceutical business. The cash position jumped from ₹0.36 crore to ₹10.99 crore as a result. The key now is whether management uses that cash to scale the core business or lets the one-off define the year. The land sale was flagged in earlier quarters, so the profit was not a surprise. The real test is next year's P&L without it.

Primary source: BSE · NSE

Phaarmasia approves FY26 results. The filing omits the numbers.

Tipsheet Editorial — Fri, 29 May 2026 19:18:08 GMT

A procedural cover letter. The board signed off on annual results and named new auditors, but the actual financials are missing.

What’s new

Board approved audited results for Q4 and FY26 on March 31, 2026.
Appointed internal and secretarial auditors for the upcoming compliance cycle.
The filing contains no revenue, profit, or dividend figures.

Why it matters

This is a procedural milestone, not a financial update. The approval is a regulatory prerequisite for publishing the actual numbers. For a ₹53 crore nano-cap, the filing confirms the process is complete but gives the market nothing new to price.

What we’re watching

The detailed financial statements in the separate announcement.
Whether the new auditors flag any qualifications in their report.
Any operational commentary from management on the FY26 performance.

The full read

Phaarmasia's board signed off on its annual results. That's the entire news. The cover letter approves the Q4 and FY26 numbers and names new auditors for the coming year. It provides no financial metrics, no dividend, and no operational detail. For a ₹53 crore nano-cap, the filing is a compliance checkbox. It is not a source of new information. The actual numbers will tell the story. They aren't here.

Primary source: BSE · NSE